The group's co-authored "Construction and Acceptance Standard for Clean Rooms in the Pharmaceutical Industry" has been approved as a national standard.
Release time:
2025-05-23
The group's co-authored "Construction and Acceptance Standard for Clean Rooms in the Pharmaceutical Industry" has been approved as a national standard
On May 21, the group's co-authored "Construction and Acceptance Standard for Clean Rooms in the Pharmaceutical Industry" was approved as a national standard by the Ministry of Housing and Urban-Rural Development, with the number GB/T51466-2025, and will be implemented on September 1, 2025.
This standard is based on the original national standard for the construction of clean rooms in the pharmaceutical and electronics industries, and has been systematically optimized to meet the specific needs of the pharmaceutical industry. It emphasizes the process characteristics and technical requirements of pharmaceutical clean engineering. Jiangsu Qi'an, as a major participating unit, and Xu Bing, deputy general manager of the group, as a member of the standard drafting group, leveraged their years of experience in the pharmaceutical clean engineering field to provide professional technical content, including construction specifications for clean pipe systems, commissioning and testing standards for clean air conditioning systems, and acceptance procedures for clean color-coated steel plate enclosure structures. In particular, the innovative achievements accumulated by the company, such as CMA-certified clean room construction experience and the FDA standard clean room maintenance system, have been integrated into the standard clauses, making the new national standard more instructive and practical in terms of construction processes and acceptance indicators.
First-class enterprises set standards! This participation in the national standard fully demonstrates Jiangsu Qi'an's leading technical strength in the field of pharmaceutical clean engineering, provides strong technical support for the group's further expansion into strategic emerging markets such as biomedicine and high-end medical devices, and makes Jiangsu Qi'an's due contribution to promoting the standardization of China's pharmaceutical clean engineering. (Jinhui Branch) 
Recommended news
2026-10-08
In late September, the China Construction Enterprise Management Association organized an experience-sharing and on-site observation conference on quality and safety management in construction projects in Guangzhou, which was attended by representatives from the Group.
2026-09-21
Empowering Communities Through Health: Experts Bring Science-Based Education to Qian’an
On September 18, Jiangsu Qian’an Construction Group, in collaboration with the Science Education Base of Qidong People’s Hospital, hosted the 2026 National Science Popularization Event.
2026-09-18
In mid-September, a foreign‑owned expert audit team from Jotun’s Norwegian headquarters conducted a three‑day, headquarter‑level specialized safety audit on the Jotun Zhangjiagang project site undertaken by the Group.
2026-09-18
The Roche (Shanghai) project of the Group has successfully achieved 2 million safe man-hours.
On September 17, the Roche (Shanghai) Biopharmaceutical Production Base project, undertaken by the Group, successfully reached the milestone of 2 million safe man-hours.
2026-09-18
On September 16–17, the China Chemical Construction Enterprises Association held a training course on building “Quality‑Trusted Work Teams” in Chengdu, with representatives from the Group in attendance. The session featured a live lecture by Shi Jie, a senior expert of the Association.
2026-09-09
Good News Abounds | The Group Has Secured Multiple Emerging Industry Projects in Succession
In the golden autumn season, bountiful harvests abound, and new‑generation growth sectors showcase their strength. Since August, leveraging its deep-rooted expertise and core competencies in industrial installation, the Group has successively won bids for five key projects in emerging productivity fields, with a total contract value exceeding RMB 250 million, injecting robust momentum into its resilient year‑end performance.